
Gilead to acquire Ouro Medicines in deal exceeding 2 billion dollars to expand biotech pipeline
Gilead Sciences has announced plans to acquire privately held biotechnology firm Ouro Medicines in a deal valued at up to 2.18 billion dollars, signaling continued












